Labeled Quantitative Proteomics

Proteomics

Labeled Quantitative Proteomics

Label-free Quantitative Proteomics

DIA Proteome Analysis Technology

PRM-targeted Proteomics

Post-translational Modification Omics

Labeled Quantitative Proteomics

TMT/iTRAQ Quantitative Proteomic Expression Profiling

iTRAQ (Isobaric Tag for Relative Absolute Quantitation) and TMT (Tandem Mass Tags) technologies are peptide in vitro labeling and quantification technologies developed by AB Sciex and Thermo respectively. Different labeling reagents are combined with trypsin-digested peptides from different samples, separated by chromatography, and passed through MS and MS/MS. The neutral loss of the balance group occurs in the secondary mass spectrometry, while the reporter group generates multiple reporter ions in the low-mass region of the secondary mass spectrometer, and their signal intensities represent the expression levels of the labeled sample respectively. The ratio of the same peptide fragment of the protein between different samples, so as to achieve the relative quantification of the protein.


Research Process


Products Advantages

Full coverage

Sample types are not restricted

Accurate quantification and good repeatability

One-time on-machine, avoid batch-to-batch error


Sample Requirements


Analysis Results


Case Analysis

The AKT-Independent MET–V-ATPase–MTOR Axis Suppresses Liver Cancer Vaccination

Journal: Signal Transduction and Targeted Therapy       Impact factor: 13.493 Published date: August, 2020       Published by: Zhejiang University

Research Background

Because of the high mortality rate, the early diagnosis and treatment of liver cancer are still difficult. Vaccination is considered to be an ideal means of prevention and adjuvant therapy, but there is no official vaccine for HCC, and the immunosuppressive molecular mechanism of HCC is unknown.This article focuses on the MET proteins involved in the immunogenicity of liver cancer, and discovers a MET-V-ATPase-MTOR pathway that is independent of the canonical MET-AKT-MTOR pathway and its potential role in liver cancer intervention.

Correlation scatter plot analysis

Differential protein GO enrichment map

Conclusion

The article found that MET act as a "gate-keeper" for suppressing liver cancer immunogenicity. Proteome detection found that it was independent of the downstream target V-ATPase outside the classical Akt pathway. The efficacy of chemotherapy-based liver cancer vaccination was markedly enhanced by targeting the MET–V-ATPase–MTOR axis, highlighting a translational strategy for identifying MET-associated drug candidates for cancer prevention.

Reference

Huang Xing,Xu Xingyuan,Wang Xun et al. The AKT-independent MET-V-ATPase-MTOR axis suppresses liver cancer vaccination.[J] .Signal Transduct Target Ther, 2020, 5: 122

© Copyright 2015-2022 Suzhou PANOMIX Biomedical Tech Co.,Ltd